DETAILED ACTION
Receipt of Arguments/Remarks filed on August 24 2026 is acknowledged. Claims 1-2 and 4-7 were amended. Claims 1-12 are pending. Claims 7-12 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on December 23 2025. Claims 1-6 are directed to the elected invention.
In light of the amendments to claim, the species election has been expanded to the 9 specific compounds claimed.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
The effective filing date of the instant claims is February 25 2022.
Withdrawn Objection/Rejections
The amendments filed August 24 2026 are sufficient to overcome the objection to the drawings. The structures in the drawings are legible.
The amendments filed August 24 2026 are partially sufficient to overcome the objections of claim 1. The claim was amended to recite the full name of the acronyms TCF/LEF. The claim was amended to insert “a” before condition. Thus these amendments were sufficient to overcome these particular objections.
The amendments filed august 24 2026 are sufficient to overcome the rejection of claims 1-6 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph. Claim 1 was amended to clarify the structure of the claimed compounds. While the response does not indicate where support for the amended to the claimed compounds can be found in the specification nor does the specification provide explicit support for the amendment to the compounds, the position of the examiner is that this was a typographical error and that one skilled in the art would recognize that the N with two bonds is supposed to be NH. The examiner notes that the NH form of the compound(s) appear to be the commercially available form of the compound. Thus, pursuant to MPEP 2163.07 the examiner is interpreting the amendment to correct an obvious error. Claim 2 was amended to recite the pharmaceutical composition further comprises a targeting moiety. Claim 4 makes it clear that the condition is cancer or cancer stem cell growth.
The amendments filed August 24 2026 are sufficient to overcome the rejection of claims 1-6 on the basis that it contains an improper Markush grouping of alternatives. While the compounds are not all structurally similar due to the small number of compounds the improper Markush group rejection is withdrawn.
The amendments filed August 24 2026 are sufficient to overcome the rejection of claims 2 and 5 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claims now recite the structure of a specific targeting moiety which is a specific aptamer.
The amendments filed August 24 2026 are sufficient to overcome the rejection of claims 1, 3-4 and 6 under 35 U.S.C. 103 over Benej et al. (PNAS, 2018) in view of Li et al. (Oncogene, 2015); and the rejection of claims 2 and 5 under 35 U.S.C. 103 over Benej et al. in view of Li et al. as applied to claims 1, 3-4 and 6 above and in further view of Wu et al. (Mol. Pharmaceutics, 2013). None of the claimed compounds are taught by Benej et al., Li et al. or Wu et al.
Maintained/Modified and New Objections and Rejections Necessitated by the Amendments filed August 24 2026
Claim Objections
Claim 1 is objected to because of the following informalities: many of the structures are illegible. The structures are still not completely legible. For example the “3” in CH3 in many structures is difficult to read. Appropriate correction is required.
Response to Arguments
Applicants’ arguments filed August 24 2026 have been fully considered but they are not persuasive.
Applicants indicate that claim 1 was amended to improve structures. While the structures are improved, they are still not of sufficient quality. The examiner notes 37 C.F.R. 1.84 states “Character of lines, numbers, and letters. All drawings must be made by a process which will give them satisfactory reproduction characteristics. Every line, number, and letter must be durable, clean, black (except for color drawings), sufficiently dense and dark, and uniformly thick and well-defined.” Here, while the drawings were replaced with structures that are sufficient, the claims were not amended in a similar manner.
Claim Rejections - 35 USC § 112-Scope of Enablement
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1-6 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for the use GL-4, GL-21, GL-105, GL-109, GL-180, GL-208, GL-294 and GL-455 in treating cancer by way of the declaration provided August 24 2026 does not reasonably provide enablement for treating or preventing any disease or condition or preventing any cancer with all the claimed compounds. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. This is a scope of enablement rejection.
To be enabling, the specification of the patent must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557, 1561 (Fed. Cir. 1993). Explaining what is meant by “undue experimentation,” the Federal Circuit has stated:
The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed to enable the determination of how to practice a desired embodiment of the claimed invention. PPG v. Guardian, 75 F.3d 1558, 1564 (Fed. Cir. 1996).
The factors that may be considered in determining whether a disclosure would require undue experimentation are set forth by In re Wands, 8 USPQ2d 1400 (CAFC 1988) at 1404 where the court set forth the eight factors to consider when assessing if a disclosure would have required undue experimentation. Citing Ex parte Formal, 230 USPQ 546 (BdApls 1986) at 547 the court recited eight factors:
1) the quantity of experimentation necessary,
2) the amount of direction or guidance provided,
3) the presence or absence of working examples,
4) the nature of the invention,
5) the state of the prior art,
6) the relative skill of those in the art,
7) the predictability of the art, and
8) the breadth of the claims.
These factors are always applied against the background understanding that scope of enablement varies inversely with the degree of unpredictability involved. In re Fisher, 57 CCPA 1099, 1108, 427 F.2d 833, 839, 166 USPQ 18, 24 (1970). Keeping that in mind, the Wands factors are relevant to the instant fact situation for the following reasons:
The breadth of the claims and Nature of the Invention
The claim is very broad insofar as it recites treating or preventing any condition in a subject comprising administering to the subject a pharmaceutical composition comprising an effective amount of an agent that inhibits TCF/LEF transcription activity or TCF/LEF expression. The compounds claimed are structurally diverse with no central core.
The amount of direction or guidance provided and the presence or absence of working examples
The specification provides no direction or guidance for how the compounds claimed can be used to treat or prevent any condition in a subject. Fig. 4 shows the claimed compounds and TCF/LEF transcription IC50 as well as cell viability. Nothing in the specification indicates though what code corresponds to what structure. No guidance is provided in the instant specification on the test parameters utilized to determine these values. There is no indication which cells were utilized in the test. No reasonably specific guidance is provided concerning useful therapeutic protocols for treating or preventing the scope of diseases encompassed by the claims, other than stating they can be treated or prevented. None of the data actually shows that administration of the composition in a subject would treat or prevent any condition. Even in a narrower interpretation with a subject with cancer, none of the data actually shows an effect on tumor size reduction or treating/preventing all forms of cancer. Newly submitted declaration under Rule 132 shows compounds GL-4, GL-21, GL-105, GL-109, GL-180, GL-208, GL-294 and GL-455 and their corresponding structures. The declaration shows the effect of these compounds in various cancer cell lines and their corresponding IC50. However, no data is shown for the first claimed compound:
PNG
media_image1.png
250
177
media_image1.png
Greyscale
.
The Relative Skill Level, the State of the Prior Art and The Level of
Predictability in the Art
The relative skill of those in the art is high, that of an MD or PHD. A medicinal chemist who understands both drug design as well as therapeutic protocols.
Amerigo Scientific teaches that the T cell factor (TCF) family is an important switch in controlling cancer. In some tumors, upregulation of TCF factors may cause T cells to suppress tumor immune responses and promote tumor growth and metastasis (overview). TCF1 and LEF1 mainly play a role in immune cell differentiation and T cell development. In leukemia, abnormal activation may promote T cell malignant proliferation. Epigenetic modifications can inhibit TCF3 in some cancer which leads to release of Wnt signal initiation and stimulates cancer progression. High expression of TCF4 can enhance cell stemness and tumor resistance, making cancer cells more invasive (the role of TCF). T-cell factor family members directly linked to several cancer types including colorectal cancer, breast cancer, acute myeloid leukemia, gastric cancer and hepatocellular carcinoma (see table).
Takano et al. is directed to TCF/LEF-mediated transcriptional regulation in the canonical Wnt pathway. The TCF/LEF family consists of sequence-specific transcription factors that serve as the final key regulators in the Wnt/β-catenin pathway. These proteins bind to Wnt response elements (WREs) in target gene enhancers and promoters, thereby determining which genes are regulated by Wnt signaling/ Despite their fundamental similarities, each TCF/LEF family member can generate distinct effects on target genes, shaped by differential expression patterns, alternative splicing events, and protein–protein interactions (PPIs). TCF7 and LEF1 function primarily as activators of Wnt target genes, particularly in colorectal tumors. Dysregulation of these factors contributes to disease. TCF7L2 polymorphisms are associated with type 2 diabetes and upregulation of TCFL2 is observed in neurogenerative conditions such as Alzheimer’s disease (section 3). Multiple Wnt/β-catenin-targeted agents are in development or have been tested previously. Many efforts to pharmacologically manipulate the Wnt pathway have focused on upstream targets using both biologics and small molecules. However, mutations that aberrantly activate the Wnt pathway often occur downstream. Furthermore, the demonstrated clinical toxicity associated with broad upstream perturbation of the Wnt signaling cascade (e.g., Wnt/Fzd inhibition or Porcupine inhibitors) may limit the therapeutic utility of such agents (section 11). It is important to note that many of β-catenin/TCF inhibitors discovered to date contain promiscuous chemical structures, including compounds later identified as pan-assay interference compounds (PAINS), which can cause non-specific interference in assays, as well as an organocopper complex with potential toxicity concerns. Consequently, these initial hits require rigorous counter screen and further structural optimization to validate their specific mechanism of action and assess their therapeutic potential (section 11). Despite the crucial role of Wnt signaling in diseases such as cancer and fibrosis and the demonstrated efficacy of Wnt-targeting therapies in improving pathological conditions in animal models, no drugs that target Wnt signaling have been clinically approved. The intrinsic complexity of the Wnt signaling cascade, along with its extensive cross-talk with multiple pathways, represents a significant obstacle to safe therapeutic targeting. Nevertheless, the clinical efficacy of pharmacological modulation of the Wnt signaling pathway remains high. For example, recent studies have suggested that inhibition of the Wnt/β-catenin pathway, at least in preclinical models, synergizes with immunotherapies, including immune checkpoint inhibitors and CAR-T-cell therapies, through intrinsic effects on immune cells, tumors, and the tumor microenvironment (second to last paragraph).
Lofmark et al. (Clin Pharmacol Ther. 2020) teaches that high in vitro drug potency does not necessarily predict in vivo benefit, partly because of poorer pharmacokinetic properties (page 299, left column, first paragraph).
Thus, the state of the art establishes that only in some tumors upregulation of TCF factors may cause T cells to suppress tumor immune responses and promote tumor growth and metastasis. Each TCF/LEF family member can generate distinct effects on target genes and the intrinsic complexity of the Wnt signaling cascade, along with its extensive cross-talk with multiple pathways, represents a significant obstacle to safe therapeutic targeting. Administration of an instantly claimed inhibitor to a specific tumor showed no appreciable reduction of growth tumor. Finally that a high in vitro drug potency does not necessarily predict in vivo benefit.
The quantity of experimentation necessary
Because of the known unpredictability of the art, and in the absence of experimental evidence, no one skilled in the art would accept the assertion that the instantly claimed agents could be predictably used to treat or prevent any condition which includes cancer, Alzheimer’s, fibrosis, etc. as inferred by the claim and contemplated by the specification. Accordingly, the instant claims do not comply with the enablement requirement of §112, since to practice the invention claimed in the patent a person of ordinary skill in the art would have to engage in undue experimentation, with no assurance of success.
Response to Arguments/Declaration under Rule 132
Applicants’ arguments filed August 24 2026 have been fully considered but they are not persuasive.
Applicants argue that the specification enables the claimed invention without undue experimentation. It is argued that the rejection appears to impose an improper requirement that the specification demonstrate actual therapeutic efficacy such as in vivo tumor reduction or clinical benefit and such a requirement is not mandated under 112(a). It is argued that the enablement standard requires that the specification teach a person of ordinary skill in the art how to make and use the claimed invention without undue experimentation. Here the specification provides meaning in vitro data demonstrating biological activity directly relevant to the claimed mechanism. The specification shows assays which are well-established and widely accepted in the art for evaluating transcription inhibition and anti-proliferative effects. It is argued that the examiner indicates unpredictability of the Wnt/TCF pathway and limitations of in vitro data, the law does not require absolute predictability.
Regarding Applicants’ arguments, while Applicants are correct and there are no per se rules about in vivo experiments being required for enablement nor is there a requirement that working examples are required. In unpredictable arts, MPEP 2164.02 makes it clear that lack of a working example is a factor to be considered. MPEP 2164.03 discusses the relationship of predictability of the art and the enablement requirement. Applicants argue that the assays shown in the specification are well-established and widely accepted. While Applicants argue this, support for this statement is not provided. Sharma et al. (Nature Review Cancer, 2010) teaches that tumor cells growing in 3D cultures are generally believed to more closely mimic their counterparts in vivo (page 248, left column). Figure 1 shows 3D cell culture assays. Gordon (Diseases, 2018) also confirms that 3D tumor spheroid models more closely model physiological conditions (section 2.9). The declaration filed August 24 2026 clearly shows the compounds in an organoid cell viability assay (Fig. A3) which is a 3D tumor spheroid model (see pt. 6, bottom of page 2 of the declaration). Therefore, with regards to treating cancer, the examiner can agree that G-4, GL-21, GL-105, GL-109, GL-180, GL-208, GL-294 and GL-455 are enabled. However, the claims are much broader than that. They encompass treating or preventing any condition or preventing any cancer. Nothing in the specification nor the declaration establish that the compounds can be used to treat the full breadth of the conditions encompassed by the claims or prevent any condition. In Genentech Inc. v. Novo Nordisk A/S, 108 F.3d 1361, 1366 Fed. Cir. 1997 states that "a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion" and "patent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable." Therefore, while absolute predictability is not required, there is some degree of predictability required. No other diseases are shown to be treated with the claimed compounds, nowhere in the declaration is it stated that the compounds can be used to prevent any cancer and finally, the first claimed structure is not utilized in the declaration.
The declaration under 37 CFR 1.132 filed 132 is insufficient to overcome the rejection of claims 1-6 based upon 112a enablement as set forth in the last Office action because: while the declaration does show 8 of the 9 claimed compounds in various different cancer cell lines had IC50 in at least the micromolar range and thus would enable the use of these compounds in treating cancer in these various cell lines, does not establish that the claimed compound can be used to treat or prevent any condition with the 9 claimed agents or that the 9ed claimed agents can be utilized to treat or prevent any cancer in a subject. The declaration does a very good job of clearly indicating which compound goes with which code and explaining the tests performed. As indicated above, the declaration clearly establishes that G-4, GL-21, GL-105, GL-109, GL-180, GL-208, GL-294 and GL-455 are enabled for treating cancer. But no other conditions within the scope are discussed in the declaration and nothing in the declaration indicates that the compounds as shown can prevent cancer.
Claim Rejections - 35 USC § 112-New Matter
The following is a quotation of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), first paragraph:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 2 and 5 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection.
Claims 2 and 5 introduce new matter as the claims recite the limitation: "pharmaceutical composition further comprises a targeting moiety” and “wherein said targeting moiety is an AS1411 aptamer”. There is no support in the specification for these limitations.
Regarding claim 2, firstly, the examiner notes that page 9 of the remarks filed August 24 2026 indicate that claim 2 was amended to clarify that the agent further comprises a targeting moiety. If claim 2 had been amended in this manner then the examiner would agree that this would overcome the previously identified rejection under 112(b) and not be considered new matter. However, that is not how claim 2 was amended. Claim 2 recites the said pharmaceutical composition further comprises a targeting moiety. This does not require the targeting moiety to be part of the agent but instead could be a separate component of the composition. The specification teaches that targeting agent can be conjugated to nanoparticles (page 2); aptamers (targeting moieties) can be chemically linked or conjugated to nucleic acid inhibitors to form targeted nucleic acid inhibitors (page 11). But the specification never teaches that the pharmaceutical composition can just comprise a targeting moiety.
Regarding claims 2 and 5, Applicants indicate support for AS1411 can be found on page 9, but this is not found on page 9. Perhaps Applicants meant page 11 as this page discusses aptamers. Nonetheless, this portion of the specification does not provide support for this claim limitation. Firstly, nothing in the specification mentions AS1411. In the response filed August 24 2026 (see page 8, first complete paragraph), Applicants point to Ray et al. As indicated previously the examiner noted that the specification directs the reader’s attention to Ray et al. and Ray et al. teaches AS1411. While this particular species does provide support for the structure-function relationship recited in the claims, the specification doesn’t actually teach this species. Ray et al. is an NPL document. Nothing on page 11 of the specification indicates any intention to incorporate by reference any teaching in Ray et al. Even if there has been a statement to incorporate the teachings of Ray et al., nothing in the paragraph indicates with clear intention what material is intended to be incorporated. Finally, the MPEP is clear, incorporation by reference of essential subject matter cannot be to a NPL document. 37 CFR 1.57(b) makes it clear that an incorporation by reference must (1) express a clear intent to incorporate by reference by using the root words “incorporat(e)” and “reference” and (2) clearly identify the references publication. 37 CFR 1.57 (c) indicates that essential subject matter may only be incorporated by reference to a US Patent or US PGPUB. Essential material is that which provides written description of the invention. Therefore, since the specification fails to clearly convey an intent to incorporate the material by reference, the amendment to the claims is considered new matter. It is noted that corrections under 37 CFR 1.57(h) states: (h) An incorporation of material by reference that does not comply with paragraphs (c), (d) or (e) of this section is not effective to incorporate such material unless corrected within any time period set by the Office, but in no case later than the close of prosecution as defined by § 1.114(b) , or abandonment of the application, whichever occurs earlier. In addition:
(1) A correction to comply with paragraph (c)(1) of this section is permitted only if the application as filed clearly conveys an intent to incorporate the material by reference. A mere reference to material does not convey an intent to incorporate the material by reference.
(2) A correction to comply with paragraph (c)(2) of this section is only permitted for material that was sufficiently described to uniquely identify the document.
Therefore, it is the Examiner’s position that the disclosure does not reasonably convey that the inventor had possession of the subject matter of the amendment at the time of filing of the instant application.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1, 3-4 and 6 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12 of US Patent No. 12728115 (copending Application No. 17671515) in view of Yu (Scientific Reports, 2017). Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims overlap in scope.
The instant application claims a method for treating or preventing condition in a subject, comprising administering to the subject a pharmaceutical composition comprising an effective amount of an agent that inhibits TCF/LEF transcriptional activity, or TCF/LEF expression, wherein said agent is at least one small molecule represented by a compound having the chemical structure of:
PNG
media_image2.png
200
400
media_image2.png
Greyscale
(as elected).
Patent ‘115 claims a method for treating cancer in a subject, comprising administering to the subject a pharmaceutical composition comprising an effective amount of at least one agent that inhibits at least one of EN2 expression or EN2 transcriptional activity, and at least one of SATB2 expression or SATB2 transcriptional activity, wherein SATB2 and EN2 are expressed in the cancer, the cancer is selected from the group consisting of human breast cancer, prostate cancer, colorectal cancer, pancreatic cancer, gastric cancer, liver cancer, lung cancer, cancer stem cells, mesothelioma, brain cancer, ovarian cancer, head and neck cancer, sarcoma, kidney cancer, melanoma, multiple myeloma, leukemia, and lymphoma, and the at least one agent wherein the claimed agents include the same compound as instantly elected is claimed (see page 4, last line, second compound).
Regarding claim 4, Patent ‘115 claims the same (claim 4).
Regarding claim 6, Patent ‘115 claims the same (claim 6).
The difference between the instant claims and Patent ‘115 is that Patent ‘115 claims a specific condition (i.e. treating or preventing cancer) and claims that the agent inhibits at least one of EN2 expression or EN2 transcriptional activity and at least one of SATB2 expression or SATB2 transcriptional activity. Patent ‘115 does claim administration of the same compound. Patent ‘115 does not claim TCF/LEF expression. However, this deficiency is cured by Yu et al.
Yu et al. is directed to SAT2/beta-catenin/TCF-LEF pathway which induces cellular transformation by generating cancer stem cells in colorectal cancer. SATB2 is highly expressed in colon cancer cell lines. Silencing of SATB2 inhibits TCF/LEF activity and its targets (page 2, third complete paragraph). IHC data demonstrated that SATB2 expression is positively correlated with β-catenin expression. Examined whether β-catenin/TCF-LEF pathway mediates the effects of SATB2 in CSCs by measuring the expression of β-catenin and TCF-LEF targets, and TCF-LEF transcriptional activity. SATB2 shRNA inhibited the expression of SATB2, and β-catenin expression, and TCF/LEF targets cyclin D1 and Survivin (Fig. 7G). Furthermore, inhibition of SATB2 by shRNA attenuated TCF-LEF transcriptional activity (page 7). Data demonstrate that β-catenin/TCF-LEF pathway mediates the biological effects of SATB2 (page 8).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of Patent ‘115 and Yu et al. and measure the transcriptional activity of TCF/LEF. One skilled in the art would have been motivated to measure this activity as Patent ‘115 specifically claims the compounds inhibit SATB2 and Yu et al. demonstrates that SATB2 inhibitors inhibit expression of SATB2 and beta-catenin which attenuated TCF-LEF transcription. Since the data in Yu et al. demonstrates a link between TCF-LEF pathway and SATB2, one skilled in the art would have a reasonable expectation of success.
Claims 2 and 5 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12 of US Patent No. 12728115 (copending Application No. 17671515) in view of Yu (Scientific Reports, 2017) as applied to claims 1, 3-4 and 6 above and in further view of Wu et al. (Mol. Pharmaceutics, 2013, cited in the Office action mailed 2/23/25). Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims overlap in scope.
The instant application claims the aptamer is AS1411.
The claims of patent ‘115 are set forth above. Patent ‘115 claims a method of treating cancer. Patent ‘115 claims an aptamer. However, Patent ‘115 does not claim the aptamer is AS1411. However, this deficiency is cured by Wu et al.
Wu et al. is directed to nucleolin targeting AS1411 modified protein nanoparticle for antitumor drug delivery. Taught are nanoparticles loaded with drug to which AS1411 was attached to the surface. Compared with just nanoparticles of drug, the uptake of the AS1411 modified nanoparticles was increased in tumor cells while there was a decrease in nontumor cell lines (abstract; page 3556; Fig. 1). The nanoparticles also included a hydrophobic fluorescent dye coumarin aka imaging agent, specifically coumarin-6. The fluorescent nanoparticles were used to display the location of the nanoparticles (page 3559, cellular uptake of Apt-NPs-PTX).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of Patent ‘115, Yu and Wu et al. and utilize AS1411 modified nanoparticles/ One skilled in the art would have been motivated to utilize AS1411 targeted nanoparticles as they are taught by Wu et al. as increasing uptake in tumor cells which would be desirable with the method of Patent ‘115. Since Patent ‘115 claims nanoparticles with a targeting agent and targeting agents include aptamers there is a reasonable expectation of success.
Claims 1, 3-4 and 6 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3 and 5-6 of copending Application No. 17672693 (USPGPUB No. 20220168422) in view of Yu et al. Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims overlap in scope.
This is a provisional nonstatutory double patenting rejection.
The instant claims are set forth above.
Copending ‘693 claims a method for treating or preventing cancer in a subject, comprising administering to the subject a pharmaceutical composition comprising an effective amount of an agent that inhibits Nanog expression, or Nanog transcriptional activity, wherein Nanog is expressed in the cancer and the agent is the same as instantly elected (first compound listed).
Regarding claim 6, copending ‘693 claims the same (claim 6).
The difference between the instant claims and copending ‘693 is that copending ‘693 claims a specific condition (i.e. treating or preventing cancer) and claims that the agent inhibits Nanog expression or transcription activity. Copending ‘693 does claim administration of the same compound. Copending ‘693 does not claim TCF/LEF expression. However, this deficiency is cured by Yu et al.
Yu et al. is directed to SAT2/beta-catenin/TCF-LEF pathway which induces cellular transformation by generating cancer stem cells in colorectal cancer. The pluripotency maintaining factors (Nanog) regulate self-renewal and survival of stem cells (page 2, first paragraph). Some of the targets of TCF/LEF include pluripotency maintaining factors such as Nanog (page 2, second complete paragraph). SATB2 shRNA inhibited the expression of TCF-LEF target genes, Nanog in colorectal CSCs (page 10, last paragraph).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of copending ‘693 and Yu et al. and measure the transcriptional activity of TCF/LEF. One skilled in the art would have been motivated to measure this activity as copending ‘693 specifically claims the compounds inhibit Nanog and Yu et al. demonstrates that Nanog is a TCF-LEF target gene. Since Nanog is a target gene of TCF-LEF there is a reasonable expectation of success.
Regarding claim 4, Yu et al. teaches that Nanog regulate self-renewal and survival of stem cells. Therefore, administration of the elected compound, which is taught by copending ‘693 as an inhibitor of Nanog would be expected to inhibit cancer stem cell growth.
Claims 2 and 5 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3 and 5-6 of copending Application No. 17672693 (USPGPUB No. 20220168422) in view of Yu et al. as applied to claims 1, 3-4 and 6 above and in further view of Wu et al. (Mol. Pharmaceutics, 2013, cited in the Office action mailed 2/23/25). Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims overlap in scope.
The instant application claims the aptamer is AS1411.
The claims of copending ‘693 are set forth above. Copending ‘693 claims a method of treating cancer. Copending ‘693 claims an aptamer. However, copending ‘693 does not claim the aptamer is AS1411. However, this deficiency is cured by Wu et al.
Wu et al. is directed to nucleolin targeting AS1411 modified protein nanoparticle for antitumor drug delivery. Taught are nanoparticles loaded with drug to which AS1411 was attached to the surface. Compared with just nanoparticles of drug, the uptake of the AS1411 modified nanoparticles was increased in tumor cells while there was a decrease in nontumor cell lines (abstract; page 3556; Fig. 1). The nanoparticles also included a hydrophobic fluorescent dye coumarin aka imaging agent, specifically coumarin-6. The fluorescent nanoparticles were used to display the location of the nanoparticles (page 3559, cellular uptake of Apt-NPs-PTX).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of Copending ‘693, Yu and Wu et al. and utilize AS1411 modified nanoparticles/ One skilled in the art would have been motivated to utilize AS1411 targeted nanoparticles as they are taught by Wu et al. as increasing uptake in tumor cells which would be desirable with the method of Copending ‘693. Since Copending ‘693 claims nanoparticles with a targeting agent and targeting agents include aptamers there is a reasonable expectation of success.
Claims 1, 4 and 6 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12 of copending Application No. 17679073 (USPGPUB No. 20220233539). Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims overlap in scope.
This is a provisional nonstatutory double patenting rejection.
The instant claims are set forth above.
Copending ‘073 claims a method for treating or preventing cancer in a subject, comprising administering to the subject a pharmaceutical composition comprising an effective amount of an agent that inhibits at least one of Smoothened receptor, or Gli transcription activity. A specific compound claimed is
PNG
media_image3.png
176
397
media_image3.png
Greyscale
.
Regarding claim 4, copending ‘073 claims the same (claim 4).
Regarding claim 6, copending ‘073 claims the same (claim 6).
The difference between the instant claims and copending ‘073 is that copending ‘073 does not claim TCF/LEF expression. However, copending ‘073 claims administration of the same compound to the same patient population.
Although the reference is silent about the TCF/LEF expression, it does not appear that the claim language or limitations result in a manipulative difference in the method steps when compared to the prior art disclosure. See Bristol-Myers Squibb Company v. Ben Venue Laboratories, 58 USPQ2d 1508 (CAFC 2001). “It is a general rule that merely discovering and claiming a new benefit of an old process cannot render the process again patentable.” In re Woodruff, 16 USPQ2d 1934, 1936 (Fed. Cir. 1990). Granting a patent on the discovery of an unknown but inherent function would remove from the public that which is in the public domain by virtue of its inclusion in, or obviousness from, the prior art. In re Baxter Travenol Labs, 21 USPQ2d 1281 (Fed. Cir. 1991). See M.P.E.P. 2145. On this record, it is reasonable to conclude that the same patient is being administered the same active agent by the same mode of administration in the same amount in both the instant claims and the prior art reference. The fact that Applicant may have discovered yet another beneficial effect from the method set forth in the prior art does not mean that they are entitled to receive a patent on that method.
Thus, copending ‘073, either expressly or inherently implied, each and every limitation of the instant claims.
Claims 2 and 5 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12 of copending Application No. 17679073 (USPGPUB No. 20220233539) as applied to claims 1, 4 and 6 above and in view of Wu et al. (Mol. Pharmaceutics, 2013, cited in the Office action mailed 2/23/25). Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims overlap in scope.
The instant application claims the aptamer is AS1411.
The claims of copending ‘073 are set forth above. Copending ‘073 claims a method of treating cancer. Copending ‘073 claims an aptamer. However, copending ‘073 does not claim the aptamer is AS1411. However, this deficiency is cured by Wu et al.
The teachings of Wu et al. are set forth above.
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine the teachings of Copending ‘073, Yu and Wu et al. and utilize AS1411 modified nanoparticles/ One skilled in the art would have been motivated to utilize AS1411 targeted nanoparticles as they are taught by Wu et al. as increasing uptake in tumor cells which would be desirable with the method of Copending ‘073. Since Copending ‘073 claims nanoparticles with a targeting agent and targeting agents include aptamers there is a reasonable expectation of success.
Response to Arguments
Applicants’ arguments filed August 24 2026 are acknowledged. The rejections are maintained since applicant has not made any substantive arguments traversing the rejection. Applicant(s) is/are reminded that a request to hold a rejection in abeyance is not a proper response to a rejection. Rather, a request to hold a matter in abeyance may only be made in response to an OBJECTION or REQUIREMENTS AS TO FORM (see MPEP 714.02 and CFR 1.111(b)). Furthermore, as noted above only one of the NSDP rejections is provisional, the other is over a patent.
Conclusion
Applicants’ amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ABIGAIL VANHORN whose telephone number is (571)270-3502. The examiner can normally be reached M-Th 6 am-4 pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Neil Hammell can be reached at 571-270-5919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ABIGAIL VANHORN/ Primary Examiner, Art Unit 1636